Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. More Details
Weak fundamentals or lack of information.
Share Price & News
How has Bioxytran's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIXT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BIXT underperformed the US Biotechs industry which returned 33.9% over the past year.
Return vs Market: BIXT underperformed the US Market which returned 18.5% over the past year.
Price Volatility Vs. Market
How volatile is Bioxytran's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Bioxytran undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Bioxytran is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bioxytran has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of BIXT's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Bioxytran regulatory filings here.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Bioxytran forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioxytran has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of BIXT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Bioxytran's filings and announcementshere.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Bioxytran performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BIXT is currently unprofitable.
Growing Profit Margin: BIXT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BIXT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BIXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: BIXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Bioxytran's financial position?
Financial Position Analysis
Short Term Liabilities: BIXT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BIXT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BIXT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BIXT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIXT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BIXT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 56.7% each year
What is Bioxytran current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIXT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIXT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIXT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
David Platt (67 yo)
Dr. David Platt, Ph.D. serves as President, Chief Executive Officer and Chairman of Board of Directors at Bioxytran, Inc. Dr. Platt founded Boston Therapeutics, Inc. (also known as AVANYX Therapeutics, Inc ...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD72.00K) is below average for companies of similar size in the US market ($USD589.00K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
|Scientific Advisory Board Chairman||no data||no data||no data|
|Member of Advisory Board||1.33yrs||no data||no data|
|Independent Director||no data||no data||0.011% |
|Independent Director||no data||no data||0.0031% |
|Member of Advisory Board||1.17yrs||no data||no data|
|Member of Advisory Board||1.08yrs||no data||no data|
|Member of Advisory Board||1.25yrs||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Director||no data||no data||0.087% |
|Member of Scientific Advisory Board||1.42yrs||no data||no data|
|Independent Director||no data||no data||0.031% |
Experienced Board: BIXT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.9%.
Bioxytran, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Bioxytran, Inc.
- Ticker: BIXT
- Exchange: OTCPK
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$17.494m
- Shares outstanding: 97.19m
- Website: https://www.bioxytraninc.com
Number of Employees
- Bioxytran, Inc.
- 233 Needham Street
- Suite 300
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIXT||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Sep 2018|
Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company’s lead pharmace ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/22 00:50|
|End of Day Share Price||2020/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.